HitGen Inc
688222
Company Profile
Business description
HitGen Inc is engaged in drug research and development and provision of technical consultation, technology transfer, and technical services. The company uses DEL technology to provide research and development services for early drug discovery and transfer of new drug R&D projects.
Contact
No. 18, Section 2, Biocity Middle Road
Chengdu Tianfu International Biological City
Shuangliu District, Sichuan Province
Chengdu610093
CHNT: +86 2885197385
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
483
Stocks News & Analysis
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.
stocks
Unconventional wisdom: A modern day bank run
Is the economy and investor portfolios at risk from a potential ‘bank run’ in private credit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,839.10 | 26.30 | 0.30% |
| CAC 40 | 7,911.53 | 72.91 | -0.91% |
| DAX 40 | 23,447.29 | 142.36 | -0.60% |
| Dow JONES (US) | 46,533.25 | 144.60 | -0.31% |
| FTSE 100 | 10,261.15 | 44.00 | -0.43% |
| HKSE | 25,465.60 | 251.16 | -0.98% |
| NASDAQ | 22,092.26 | 219.72 | -0.98% |
| Nikkei 225 | 53,819.61 | 633.35 | -1.16% |
| NZX 50 Index | 13,187.34 | 11.95 | -0.09% |
| S&P 500 | 6,628.85 | 43.77 | -0.66% |
| S&P/ASX 200 | 8,617.10 | 29.20 | 0.34% |
| SSE Composite Index | 4,095.45 | 33.65 | -0.82% |